小年刚过，新年的喜庆氛围浸润着丹江两岸。 2月11日下午，河南省淅川县丹阳迎宾馆内暖意融融，全县企业家新春座谈会在此举行。会场内座 无虚席，没有主席台与听众席的泾渭分明，政企双方面对面围坐，一场关乎新一年发展大计的恳谈，在 坦诚与期待中开篇。 "今天请大家来，就是希望大家敞开胸怀谈心声、集思广益谋发展，确保座谈会开出精气神、开出 高质量、开出新气象。"会议主持人开门见山，话语朴实，却一下子拉近了政企距离。窗外寒意未退， 室内已是暖流涌动。 亮眼的数据背后，是产业集群的强力支撑。2025年，淅川县四大产业集群产值突破80亿元。其中， 汽车零部件产业在龙头企业淅减公司带动下，主动拥抱新能源汽车赛道，行业产值同比激增39%；现代 中医药产业稳健增长，福森药业、度帮中药等企业产销两旺；新材料、新能源产业动能强劲，一批新建 项目投产达效，绿色低碳发展路径愈加清晰。与此同时，豫西南县域最大商业综合体"万悦汇"的崛起， 佳兴伞业等企业创造的"家门口就业"岗位，官福山居民宿摘得省级五星……共同绘就了一幅一二三产协 同、高质量发展活力迸发的县域经济新图景。 作为南水北调中线工程核心水源地与渠首所在地，淅川始终将壮大民营经济、推 ...

2月6日，港股中药（核心股）股盘初强势，其中，中国中药一度涨超8%，目前回落至3%，位元堂涨 5.8%，同仁堂国药、福森药业涨超1%，白云山、同仁堂科技、吉林长龙药业跟涨。 消息上，工信部等八部门印发《中药（核心股）工业高质量发展实施方案（2026—2030年）》。其中提 到，到2030年，中药工业全产业链协同发展体系初步形成，重点中药原料持续稳定供应能力进一步增 强，数智化、绿色化水平明显提升，一批关键技术取得突破，产业协同创新水平显著提高。运用人工智 能、大数据等新一代信息技术，构建经典名方、名老中医经验方等特色方剂知识图谱和图神经网络；到 2030年中药工业全产业链协同发展体系初步形成。 有分析指，该方案对中药（核心股）股是一个系统性的、中长期的重大政策利好。它将从顶层设计上推 动整个产业升级，核心是告别"粗放增长"，转向"品质和价值驱动"。这份方案是未来五年中药产业发展 的"总纲领"。它不是简单的短期刺激，而是通过提升行业门槛、鼓励创新和智能化，驱动一场深刻的供 给侧改革。 | 代码 | 名称 | 最新价 | 涨跌幅 ▽ | | --- | --- | --- | --- | | 00897 | 位元 ...

有分析指，该方案对中药股是一个系统性的、中长期的重大政策利好。它将从顶层设计上推动整个产业 升级，核心是告别"粗放增长"，转向"品质和价值驱动"。这份方案是未来五年中药产业发展的"总纲 领"。它不是简单的短期刺激，而是通过提升行业门槛、鼓励创新和智能化，驱动一场深刻的供给侧改 革。 港股中药股盘初强势，其中，中国中药一度涨超8%，目前回落至3%，位元堂涨5.8%，同仁堂国药、福 森药业涨超1%，白云山、同仁堂科技、吉林长龙药业跟涨。 消息上，工信部等八部门印发《中药工业高质量发展实施方案（2026—2030年）》。其中提到，到2030 年，中药工业全产业链协同发展体系初步形成，重点中药原料持续稳定供应能力进一步增强，数智化、 绿色化水平明显提升，一批关键技术取得突破，产业协同创新水平显著提高。运用人工智能、大数据等 新一代信息技术，构建经典名方、名老中医经验方等特色方剂知识图谱和图神经网络；到2030年中药工 业全产业链协同发展体系初步形成。 | 代码 | 名称 | 最新价 | 涨跌幅 ▽ | | --- | --- | --- | --- | | 00897 | 位元堂 | 0.365 | 5.80% | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 福森藥業有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01652 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | 本月底法定/註冊股本總額： HKD 20,000,00 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 福森藥業有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01652 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | 本月底法定/註 ...

Core Viewpoint - Fosen Pharmaceutical (01652.HK) has received approval from the National Medical Products Administration of China for its potassium hydrogen phosphate injection, branded as "Shanweixi," which is intended as a phosphate supplement [1] Group 1: Product Details - The potassium hydrogen phosphate injection is primarily used for parenteral nutrition when oral or enteral nutrition is not feasible, insufficient, or contraindicated [1] - It is also indicated for adults and children suffering from hypophosphatemia [1] - The product is classified as a Category B item under the National Medical Insurance Bureau, highlighting its safety, rapid absorption, dual phosphate supplementation, and alignment with multiple clinical guidelines [1]

Core Viewpoint - Fosun Pharma's subsidiary has received approval from the National Medical Products Administration of China for the "Compound Potassium Hydrogen Phosphate Injection," which is intended as a phosphate supplement for patients unable to receive oral or enteral nutrition [1][2]. Group 1: Product Details - The "Compound Potassium Hydrogen Phosphate Injection" is primarily used for patients with hypophosphatemia and those requiring parenteral nutrition supplementation [1]. - This new generation phosphate-potassium compound formulation aims to quickly correct phosphate deficiency while stabilizing cell membrane potential through potassium supplementation, thereby preventing risks associated with hypophosphatemia such as rhabdomyolysis and arrhythmias [1]. - The product is classified as a Category B item by the National Healthcare Security Administration, highlighting its high safety profile, rapid absorption, dual phosphate-potassium supplementation, and alignment with multiple clinical guidelines [1]. Group 2: Market Potential - According to data from Minai Network, the domestic sales of the "Compound Potassium Hydrogen Phosphate Injection" are projected to be 343 million yuan in 2023 and 413 million yuan in 2024 [1]. - The launch of this product enhances the company's portfolio in the nutritional supplement treatment sector, providing more treatment options for adults and children suffering from hypophosphatemia and those needing parenteral phosphate supplementation [2].

Core Viewpoint - Fosen Pharmaceutical's subsidiary has received approval from the National Medical Products Administration of China for its "Compound Potassium Hydrogen Phosphate Injection," which is intended as a phosphate supplement for patients unable to receive oral or enteral nutrition [1][2] Group 1: Product Details - The "Compound Potassium Hydrogen Phosphate Injection" is primarily used for patients with hypophosphatemia and those requiring parenteral nutrition supplementation [1] - The product is a new generation phosphate-potassium compound formulation that quickly corrects phosphate deficiency while stabilizing cell membrane potential through potassium supplementation [1] - The domestic sales forecast for the injection is projected to be CNY 343 million in 2023 and CNY 413 million in 2024 [1] Group 2: Market Position and Benefits - The injection is classified as a Category B product by the National Healthcare Security Administration, highlighting its safety, rapid absorption, and dual phosphate-potassium supplementation [1] - The formulation is consistent with the reference original research product, ensuring quality control that meets or exceeds the original product standards [1] - The product offers significant risk-benefit advantages in improving laboratory results and clinical symptoms for both adult and pediatric patients with hypophosphatemia [1]

Core Viewpoint - Fosen Pharmaceutical's wholly-owned subsidiary has received approval from the National Medical Products Administration of China for the launch of "Compound Potassium Hydrogen Phosphate Injection," which is intended as a phosphate supplement for patients unable to receive oral or enteral nutrition [1][2] Group 1: Product Details - The "Compound Potassium Hydrogen Phosphate Injection" is primarily used for patients with hypophosphatemia and those requiring parenteral nutrition supplementation [1] - The product is a new generation phosphate-potassium compound formulation that quickly corrects phosphate deficiency while simultaneously stabilizing cell membrane potential to prevent risks associated with hypophosphatemia [1] - The domestic sales forecast for the injection is projected to be CNY 343 million in 2023 and CNY 413 million in 2024 [1] Group 2: Market Position and Benefits - The injection is classified as a Category B product by the National Healthcare Security Administration, highlighting its safety, rapid absorption, dual phosphate-potassium supplementation, and alignment with multiple clinical guidelines [1] - The formulation of the injection is consistent with the reference product, ensuring quality control that meets or exceeds the original product, thereby safeguarding patient safety [1] - The product offers significant risk-benefit advantages in improving laboratory results and clinical symptoms for both adult and pediatric patients with hypophosphatemia [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 福森藥業有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 欣然宣佈，本集團之全資附屬公司嘉亨（ 珠海橫琴 ）醫藥科技有限公司研發的「複 合 磷 酸 氫 鉀 注 射 液」（ 商 標 ： 膳 維 喜 ）， 上 市 申 請 已 獲 得 中 國 國 家 藥 品 監 督 管 理 局 批准，批准作為磷酸補充劑。 「複合磷酸氫鉀注射液」主要用於治療當口服或腸內營養無法進行、不足或有禁忌 時，以腸外營養補充，或患有低磷血症的成人和兒童患者。作為新一代磷鉀複合 製劑，通過科學配比磷酸氫二鉀與磷酸二氫鉀，可快速糾正磷缺乏，同時鉀元素 的 同 步 補 充 可 穩 定 細 胞 ...